Prime Medicine, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRME research report →
Range $6 – $9
Price Chart
About the company
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule.
- CEO
- Allan Reine
- IPO
- 2022
- Employees
- 146
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on PRME
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $652.03M
- P/E
- -3.28
- PEG
- -0.08
- P/S
- 160.09
- P/B
- 16.07
- EV/EBITDA
- -3.97
- Div Yield
- 0.00%
- Gross Margin
- -1025.61%
- Op Margin
- -4824.94%
- Net Margin
- -4613.11%
- ROE
- -188.27%
- ROIC
- -86.83%
Latest fiscal year · YoY change
- Revenue
- $4.63M+55.3%
- Gross Profit
- $-2,689,000-190.1%
- Op Income
- $-208,350,000
- Net Income
- $-201,142,000-2.7%
- EPS
- $-1.35+18.3%
- OCF Growth
- -32.3%
- FCF Growth
- -28.4%
- 52W High
- $6.85
- 52W Low
- $2.67
- 50D MA
- $3.23
- 200D MA
- $3.48
- Beta
- 2.35
- RSI (14)
- 59
- Avg Volume
- 3.20M
No earnings-call transcripts are available for PRME yet.
- Free Float
- 32.8%
- Shares Outstanding
- 180.62M
- Float Shares
- 59.17M
of shares held by institutions
197 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Alphabet Inc. | 16.56M | 0 |
| Blackrock, Inc. | 9.60M | ▲ 1.10M |
| Ark Investment Management LLC | 8.35M | ▲ 2.10M |
| State Street Corp | 7.58M | ▲ 1.23M |
| Vanguard Group Inc | 6.47M | ▲ 1.55M |
| T. Rowe Price Investment Management, Inc. | 5.24M | ▼ 244.56K |
| Vanguard Capital Management LLC | 4.52M | ▲ 48.48K |
| Balyasny Asset Management L.P. | 3.97M | ▼ 154.28K |
| Goldman Sachs Group Inc | 3.43M | ▲ 2.46M |
| Casdin Capital, LLC | 3.17M | 0 |
| Woodline Partners LP | 3.00M | ▲ 591 |
| Ubs Group AG | 2.79M | ▼ 93.73K |
Held by 190 ETFs
Biggest fund positions in PRME by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 5, 26 | Schenkein David P | other | 75,000 |
| Jun 5, 26 | Marrazzo Jeffrey D | other | 75,000 |
| Jun 5, 26 | NELSEN ROBERT | other | 75,000 |
| Jun 5, 26 | Kelly Michael Aaron | other | 75,000 |
| Jun 5, 26 | Foster-Cheek Kaye I | other | 75,000 |
| Jun 5, 26 | Chung Wendy | other | 75,000 |
| Jun 5, 26 | Cahill Thomas | other | 75,000 |
| Apr 16, 26 | Makhni Svetlana Ni | other | 800,000 |
| Apr 16, 26 | Makhni Svetlana Ni | other | 0 |
| Feb 26, 26 | Reine Allan | other | 1,300,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PRME coverage
Recent articles, reports, and earnings notes.
Scribe Therapeutics IPO: What Investors Need to Know
Scribe Therapeutics, Inc. (NASDAQ: SCTX) is expected to list on 2026-07-24 at a price range of $13.00 to $15.00 per share. The company is offering 7,150,000 shares, with a disclosed market cap of $123,337,500. The bull case is a differentiated CRISPR platform aimed at cardiometabolic disease; the bear case is an early-stage story with no approved products and substantial going-concern risk.
Top Gene Editing Stocks: Our 7 Picks for September 2026
A countdown of 7 gene editing stocks, with the top pick revealed last.
Want a deeper read on PRME?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
globenewswire.com · Oct 5
Prime Medicine Gets FDA Green Light for Gene Editing Study
benzinga.com · Sep 25
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
globenewswire.com · Sep 24
Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 16
Prime Drink Group Provides Bi-Weekly MCTO Status Report
globenewswire.com · Sep 10
Prime Medicine to Participate in Upcoming Investor Conferences
globenewswire.com · Sep 3
BlackRock Inc. Acquires Shares of 9,602,041 Prime Medicine, Inc. $PRME
defenseworld.net · Sep 2
Prime Medicine: Soon In The Clinic
seekingalpha.com · Aug 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.